InvestorsHub Logo
Followers 90
Posts 17402
Boards Moderated 0
Alias Born 09/06/2006

Re: TalShu post# 423659

Monday, 04/29/2024 3:40:51 PM

Monday, April 29, 2024 3:40:51 PM

Post# of 425892

1) to what molecule was he referring?


Sounded like he said "... point of departure in that we have semaglutide". That is Wegovi.

2) Could Novo Nordisk’s goal to establish a presence in the cardiovascular space in 2025, and Amarin’s BOD objective to “accelerate operational momentum”, that is execution in the short-term, converge?


Would be nice, but for now we need for AMRN to keep on plugging away and do what is in their control.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News